These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22951630)

  • 21. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
    Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
    Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV Incidence Among Pregnant and Nonpregnant Women in the FACTS-001 Trial: Implications for HIV Prevention, Especially PrEP Use.
    Rees H; Chersich MF; Munthali RJ; Brumskine W; Palanee-Phillips T; Nkala B; Ahmed K; Sebe M; Mabude Z; Nchabeleng M; Bekker LG; Kotze P; Mogodiri T; Naidoo I; Panchia R; Myer L; Lombard C; Doncel GF; Gray G; Delany-Moretlwe S
    J Acquir Immune Defic Syndr; 2021 Dec; 88(4):376-383. PubMed ID: 34710071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.
    Wandeler G; Keiser O; Mulenga L; Hoffmann CJ; Wood R; Chaweza T; Brennan A; Prozesky H; Garone D; Giddy J; Chimbetete C; Boulle A; Egger M;
    J Acquir Immune Defic Syndr; 2012 Sep; 61(1):41-8. PubMed ID: 22743595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal study on mitochondrial effects of didanosine-tenofovir combination.
    López S; Negredo E; Garrabou G; Puig J; Ruiz L; Sanjurjo E; Ramos X; Infante AB; Casademont J; Cardellach F; Clotet B; Miró O
    AIDS Res Hum Retroviruses; 2006 Jan; 22(1):33-9. PubMed ID: 16438643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.
    Landman R; Koulla-Shiro S; Sow PS; Ngolle M; Diallo MB; Guèye NF; Le Moing V; Eymard-Duvernay S; Benalycherif A; Charpentier C; Peytavin G; Delaporte E; Girard PM;
    Antivir Ther; 2014; 19(1):51-9. PubMed ID: 23970206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.
    Sunpath H; Wu B; Gordon M; Hampton J; Johnson B; Moosa MY; Ordonez C; Kuritzkes DR; Marconi VC
    AIDS; 2012 Aug; 26(13):1679-84. PubMed ID: 22739389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
    Hazra R; Gafni RI; Maldarelli F; Balis FM; Tullio AN; DeCarlo E; Worrell CJ; Steinberg SM; Flaherty J; Yale K; Kearney BP; Zeichner SL
    Pediatrics; 2005 Dec; 116(6):e846-54. PubMed ID: 16291735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initiation of highly active antiretroviral therapy among pregnant women in Cape Town, South Africa.
    Stinson K; Boulle A; Coetzee D; Abrams EJ; Myer L
    Trop Med Int Health; 2010 Jul; 15(7):825-32. PubMed ID: 20497405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Battles with donors cloud Malawi's HIV prevention plan.
    Donnelly J
    Lancet; 2011 Jul; 378(9787):215-6. PubMed ID: 21770061
    [No Abstract]   [Full Text] [Related]  

  • 30. A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
    Girard PM; Cabié A; Michelet C; Verdon R; Katlama C; Mercié P; Morand-Joubert L; Pétour P; Monchecourt F; Chêne G; Trylesinski A;
    J Antimicrob Chemother; 2009 Jul; 64(1):126-34. PubMed ID: 19403652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
    Viganò A; Aldrovandi GM; Giacomet V; Merlo M; Martelli L; Beretta S; Luraschi P; Rombolà G; Mora S
    Antivir Ther; 2005; 10(8):917-24. PubMed ID: 16430197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.
    Young B; Buchacz K; Moorman A; Wood KC; Brooks JT;
    AIDS Patient Care STDS; 2009 Aug; 23(8):589-92. PubMed ID: 19591609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiretroviral therapeutic drug monitoring in HIV-infected pregnant women: maternal immunovirological outcome at delivery and during the 18 month follow-up period.
    Nicastri E; Ivanovic J; Signore F; Tempestilli M; Bellagamba R; Viscione M; Pisani G; Vallone C; Tommasi C; Gallo AL; De Nardo P; Pucillo PL; Narciso P
    Curr HIV Res; 2012 Oct; 10(7):606-13. PubMed ID: 22762419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.
    Purdy JB; Gafni RI; Reynolds JC; Zeichner S; Hazra R
    J Pediatr; 2008 Apr; 152(4):582-4. PubMed ID: 18346519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of antiretroviral therapy on pregnancy outcome in HIV-1 positive women.
    Kowalska A; Niemiec T; El Midaoui A; Burkacka E
    Med Wieku Rozwoj; 2003; 7(4 Pt 1):459-68. PubMed ID: 15010556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients.
    Horberg M; Tang B; Towner W; Silverberg M; Bersoff-Matcha S; Hurley L; Chang J; Blank J; Quesenberry C; Klein D
    J Acquir Immune Defic Syndr; 2010 Jan; 53(1):62-9. PubMed ID: 19838127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
    Ekouevi DK; Coffie PA; Becquet R; Tonwe-Gold B; Horo A; Thiebaut R; Leroy V; Blanche S; Dabis F; Abrams EJ
    AIDS; 2008 Sep; 22(14):1815-20. PubMed ID: 18753864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression.
    Huang AJ; Núñez M
    J Int Assoc Provid AIDS Care; 2015; 14(4):360-8. PubMed ID: 25999329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of highly active antiretroviral treatment (HAART) on risk factors for vertical HIV transmission.
    Garcia-Tejedor A; Maiques V; Perales A; Lopez-Aldeguer J
    Acta Obstet Gynecol Scand; 2009; 88(8):882-7. PubMed ID: 19557554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States.
    Griner R; Williams PL; Read JS; Seage GR; Crain M; Yogev R; Hazra R; Rich K;
    AIDS Patient Care STDS; 2011 Jul; 25(7):385-94. PubMed ID: 21992592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.